Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis: AGENT IDE Subgroup Analysis
The AGENT IDE trial demonstrated that among patients with coronary in-stent restenosis (ISR), treatment with the Agent paclitaxel-coated balloon (DCB) significantly reduced the 1-year risk of target lesion failure (TLF)—a composite of ischemia-driven target lesion revascularization (TLR), target vessel-related myocardial infarction (MI), and cardiac death—compared with uncoated balloon angioplasty. The absolute risk reduction was greater in patients with multilayer ISR than in those with single-layer ISR, Dr. Ajay J. Kirtane and colleagues, Columbia University Irving Medical Center, United States, reported in the August 19 issue of the Journal of the American College of Cardiology.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
